188 related articles for article (PubMed ID: 8757618)
1. Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors.
Xia M; Gaufo GO; Wang Q; Sreedharan SP; Goetzl EJ
J Immunol; 1996 Aug; 157(3):1132-8. PubMed ID: 8757618
[TBL] [Abstract][Full Text] [Related]
2. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
3. Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane.
Xia M; Leppert D; Hauser SL; Sreedharan SP; Nelson PJ; Krensky AM; Goetzl EJ
J Immunol; 1996 Jan; 156(1):160-7. PubMed ID: 8598457
[TBL] [Abstract][Full Text] [Related]
4. T cell vasoactive intestinal peptide receptor subtype expression differs between granulomas and spleen of schistosome-infected mice.
Metwali A; Elliott D; Blum AM; Li J; Sandor M; Weinstock JV
J Immunol; 1996 Jul; 157(1):265-70. PubMed ID: 8683124
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses.
Goetzl EJ; Pankhaniya RR; Gaufo GO; Mu Y; Xia M; Sreedharan SP
Ann N Y Acad Sci; 1998 May; 840():540-50. PubMed ID: 9629281
[TBL] [Abstract][Full Text] [Related]
6. Similar involvement of VIP receptor type I and type II in lymphocyte chemotaxis.
Schratzberger P; Geiseler A; Dunzendorfer S; Reinisch N; Kähler CM; Wiedermann CJ
J Neuroimmunol; 1998 Jul; 87(1-2):73-81. PubMed ID: 9670847
[TBL] [Abstract][Full Text] [Related]
7. Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide.
Johnston JA; Taub DD; Lloyd AR; Conlon K; Oppenheim JJ; Kevlin DJ
J Immunol; 1994 Aug; 153(4):1762-8. PubMed ID: 7519212
[TBL] [Abstract][Full Text] [Related]
8. Identification of vasoactive intestinal peptide receptor subtypes in the lacrimal gland and their signal-transducing components.
Hodges RR; Zoukhri D; Sergheraert C; Zieske JD; Dartt DA
Invest Ophthalmol Vis Sci; 1997 Mar; 38(3):610-9. PubMed ID: 9071214
[TBL] [Abstract][Full Text] [Related]
9. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Delgado M; Reduta A; Sharma V; Ganea D
J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
[TBL] [Abstract][Full Text] [Related]
10. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
12. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
13. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes.
Pankhaniya R; Jabrane-Ferrat N; Gaufo GO; Sreedharan SP; Dazin P; Kaye J; Goetzl EJ
FASEB J; 1998 Jan; 12(1):119-27. PubMed ID: 9438417
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
17. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
18. [Effects of vasoactive intestinal peptide on chemotaxis of bronchial epithelial cells].
Guan CX; Zhang CQ; Qin XQ; Luo ZQ; Zhou FW; Sun XH
Sheng Li Xue Bao; 2002 Apr; 54(2):103-6. PubMed ID: 11973586
[TBL] [Abstract][Full Text] [Related]
19. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
20. Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart.
Sawmiller DR; Henning RJ; Cuevas J; Dehaven WI; Vesely DL
Neuropeptides; 2004 Oct; 38(5):289-97. PubMed ID: 15464194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
